Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care. 2006;29:1288–93.
Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293:217–28.
Malabu UH, Manickam V, Kan G, Doherty SL, Sangla KS. Calcific uremic arteriolopathy on multimodal combination therapy: still unmet goal. Int J Nephrol. 2012;2012: 390768.
Malabu U, Roberts L, Sangla K. Calciphylaxis in a morbidly obese woman with rheumatoid arthritis presenting with severe weight loss and vitamin D deficiency. Endocr Pract. 2011;17:e104–8.
Pendsey SP. Understanding diabetic foot. Int J Diabetes Dev Ctries. 2010;30:75–9.
Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2011;58:157.
Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011;124:2338–49.
Shimizu S, Hosooka T, Matsuda T, Asahara S-i, Koyanagi-Kimura M, et al. DPP4 inhibitor vildagliptin preserves-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice. J Mol Endocrinol. 2012;49:125.
Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes. Role of dipeptidyl peptidase-IV inhibition. Random Control Trial. 2012;35:2076–82.
Ahmad J, Zubair M, Malik A, Siddiqui MA, Wangnoo SK. Cathepsin-D, adiponectin, TNF-α, IL-6 and hsCRP plasma levels in subjects with diabetic foot and possible correlation with clinical variables: a multicentric study. Foot. 2012;22:194–9.
Zubair M, Malik A, Ahmad J. Plasma adiponectin, IL-6, hsCRP, and TNF-α levels in subject with diabetic foot and their correlation with clinical variables in a North Indian tertiary care hospital. Indian J Endocrinol Metab. 2012;16:769.
Tuttolomondo A, La Placa S, Di Raimondo D, Bellia C, Caruso A, et al. Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity. Cardiovasc Diabetol. 2010;9:50.
Biros E, Moran CS. Mini tryptophanyl-tRNA synthetase is required for a synthetic phenotype in vascular smooth muscle cells induced by IFN-γ-mediated β2-adrenoceptor signaling. Cytokine. 2020;127: 154940.
Marfella R, Sasso FC, Rizzo MR, Paolisso P, Barbieri M, et al. Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes. Exp Diabetes Res. 2012;2012: 892706.
Long M, Cai L, Li W, Zhang L, Guo S, et al. DPP-4 inhibitors improve diabetic wound healing via direct and indirect promotion of epithelial-mesenchymal transition and reduction of scarring. Diabetes. 2017;67:518–31.
Cai L, Cai Y, Lu ZJ, Zhang Y, Liu P. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther. 2012;37:386–98.
Mohan V, Zargar A, Chawla M, Joshi A, Ayyagari U, et al. Efficacy of a combination of metformin and vildagliptin in comparison to metformin alone in type 2 diabetes mellitus: a multicentre, retrospective, real-world evidence study. Diabetes Metab Syndr Obes. 2021;14:2925–33.
Shimodaira M, Niwa T, Nakajima K, Kobayashi M. Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes. Endocr Metab Immune Disord Drug Targets. 2015;15:223–8.
Younis A, Eskenazi D, Goldkorn R, Leor J, Naftali-Shani N, et al. The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study. Cardiovasc Diabetol. 2017; 16:69
Wiciński M, Górski K, Wódkiewicz E, Walczak M, Nowaczewska M, Malinowski B. Vasculoprotective effects of vildagliptin. Focus on atherogenesis. Int J Mol Sci. 2020; 21:2275
Bi J, Cai W, Ma T, Deng A, Ma P, et al. Protective effect of vildagliptin on TNF-α-induced chondrocyte senescence. IUBMB Life. 2019;71:978–85.
Ishida Y, Murayama H, Shinfuku Y, Taniguchi T, Sasajima T, Oyama N. Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan. Expert Opin Drug Saf. 2020;19:625–31.
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–26.
Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579–88.
Tschöp MH, Stumvoll M, Ristow M. Opposing effects of antidiabetic interventions on malignant growth and metastasis. Cell Metab. 2016;23:959–60.
Sasaki T, Hiki Y, Nagumo S, Ikeda R, Kimura H, et al. Acute onset of rheumatoid arthritis associated with administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with diabetes mellitus. Diabetol Int. 2010;1:90–2.